Nantes, State/Province — October 3, 2025 — Leads & Copy — OSE Immunotherapeutics has announced the appointment of Marc Le Bozec as interim CEO, following the termination of Nicolas Poirier’s position. The decision was made by the Board of Directors, which has commenced a formal search for a permanent Chief Executive Officer.
The Board has empowered Le Bozec to lead a strategic evaluation of OSE’s business, focusing on maximizing value across partnerships, finances, and clinical development programs. Poirier will retain his position as Chief Scientific Officer at OSE. The termination of Poirier’s CEO duties will not result in any compensation or indemnity payments.
Dr. Markus Cappel, Chairman of the Board, expressed confidence in Le Bozec’s ability to bring stability and re-engage stakeholders. Le Bozec acknowledged the need for a comprehensive review and emphasized the importance of therapeutic innovation.
Le Bozec has extensive experience in the biotech sector, including roles at Financière Arbevel, Cellectis, and CYTOO. OSE Immunotherapeutics is a biotech company focused on developing first-in-class assets in immuno-oncology and immuno-inflammation.
Contacts:
investors@ose-immuno.com
French Media Contact:
Florence Portejoie
fportejoie@fp2com.fr
+33 6 07 768 283
U.S. Media Contact:
Kate Barrette
kbarrette@rooneypartners.com
+1 212 223 0561
Source: OSE Immunotherapeutics
